These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 19756557)

  • 1. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis.
    Fasanmade AA; Adedokun OJ; Ford J; Hernandez D; Johanns J; Hu C; Davis HM; Zhou H
    Eur J Clin Pharmacol; 2009 Dec; 65(12):1211-28. PubMed ID: 19756557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
    Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
    Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis.
    Fasanmade AA; Adedokun OJ; Olson A; Strauss R; Davis HM
    Int J Clin Pharmacol Ther; 2010 May; 48(5):297-308. PubMed ID: 20420786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis.
    Xu Z; Seitz K; Fasanmade A; Ford J; Williamson P; Xu W; Davis HM; Zhou H
    J Clin Pharmacol; 2008 Jun; 48(6):681-95. PubMed ID: 18401017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients.
    Berends SE; van Steeg TJ; Ahsman MJ; Singh S; Brandse JF; D'Haens GRAM; Mathôt RAA
    J Pharmacokinet Pharmacodyn; 2019 Dec; 46(6):543-551. PubMed ID: 31489538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.
    Adedokun OJ; Sandborn WJ; Feagan BG; Rutgeerts P; Xu Z; Marano CW; Johanns J; Zhou H; Davis HM; Cornillie F; Reinisch W
    Gastroenterology; 2014 Dec; 147(6):1296-1307.e5. PubMed ID: 25173754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis.
    Adedokun OJ; Xu Z; Liao S; Strauss R; Reinisch W; Feagan BG; Sandborn WJ
    Clin Ther; 2020 Jan; 42(1):157-174.e4. PubMed ID: 31982148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.
    Järnerot G; Hertervig E; Friis-Liby I; Blomquist L; Karlén P; Grännö C; Vilien M; Ström M; Danielsson A; Verbaan H; Hellström PM; Magnuson A; Curman B
    Gastroenterology; 2005 Jun; 128(7):1805-11. PubMed ID: 15940615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
    Narwal R; Roskos LK; Robbie GJ
    Clin Pharmacokinet; 2013 Nov; 52(11):1017-27. PubMed ID: 23754736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.
    Probert CS; Hearing SD; Schreiber S; Kühbacher T; Ghosh S; Arnott ID; Forbes A
    Gut; 2003 Jul; 52(7):998-1002. PubMed ID: 12801957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study.
    Dotan I; Ron Y; Yanai H; Becker S; Fishman S; Yahav L; Ben Yehoyada M; Mould DR
    Inflamm Bowel Dis; 2014 Dec; 20(12):2247-59. PubMed ID: 25358062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies.
    Chua L; Friedrich S; Zhang XC
    Clin Pharmacokinet; 2023 Oct; 62(10):1479-1491. PubMed ID: 37610533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacokinetic comparison of anrukinzumab, an anti- IL-13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients.
    Hua F; Ribbing J; Reinisch W; Cataldi F; Martin S
    Br J Clin Pharmacol; 2015 Jul; 80(1):101-9. PubMed ID: 25614144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease.
    Rosario M; Dirks NL; Gastonguay MR; Fasanmade AA; Wyant T; Parikh A; Sandborn WJ; Feagan BG; Reinisch W; Fox I
    Aliment Pharmacol Ther; 2015 Jul; 42(2):188-202. PubMed ID: 25996351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab for induction and maintenance therapy for ulcerative colitis.
    Rutgeerts P; Sandborn WJ; Feagan BG; Reinisch W; Olson A; Johanns J; Travers S; Rachmilewitz D; Hanauer SB; Lichtenstein GR; de Villiers WJ; Present D; Sands BE; Colombel JF
    N Engl J Med; 2005 Dec; 353(23):2462-76. PubMed ID: 16339095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderately to severely active rheumatoid arthritis.
    Palaparthy R; Rehman MI; von Richter O; Yin D
    Expert Opin Biol Ther; 2019 Oct; 19(10):1065-1074. PubMed ID: 31284794
    [No Abstract]   [Full Text] [Related]  

  • 19. A pharmacokinetic approach to model-guided design of infliximab schedules in ulcerative colitis patients.
    Pérez-Pitarch A; Ferriols-Lisart R; Alós-Almiñana M; Mínguez-Pérez M
    Rev Esp Enferm Dig; 2015 Mar; 107(3):137-42. PubMed ID: 25733037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis.
    Xu Y; Adedokun OJ; Chan D; Hu C; Xu Z; Strauss RS; Hyams JS; Turner D; Zhou H
    J Clin Pharmacol; 2019 Apr; 59(4):590-604. PubMed ID: 30536638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.